# Ethyreal Bio, Inc.: Phase 1 study in Thyroid Eye Disease (TED), Graves' Disease (72 participants)

**Score:** 40/100

| Field | Value |
|---|---|
| Sponsor | Ethyreal Bio, Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Evaluation of ETHY-001 for Safety, Tolerability, and Clinical Activity in Thyroid Eye Disease |
| NCT ID | NCT07885605 |
| Phase | Phase 1 |
| Status | recruiting |
| Conditions | Thyroid Eye Disease (TED); Graves' Disease; Eye Diseases, Hereditary; Eye Diseases; Exophthalmos; Orbital Diseases |
| Intervention types | drug, other |
| Target enrollment | 72 |
| Site countries | United States |
| Posted | 2026-10-21 |
| Planned start | 2026-07-06 |
| Event | Newly registered study |
| Event date | 2026-10-21 |

## Why this score
- Industry sponsor (buys outsourced services).

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07885605). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.